A Phase 2 Open-Label, Multicenter, Dose Optimization Clinical Study Of The Safety, Tolerability, And Pharmacokinetic (Pk) And Pharmacodynamic (Pd) Profiles Of Cfi-400945 As A Single Agent Or In Combination With Azacitidine Or Decitabine In Patients With Acute Myeloid Leukemia